At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Drug Treatment Study for Boys with Duchenne Muscular Dystrophy

Clinical Trial Title: 
A multi-site, randomized, placebo-controlled, double-blind, multiple ascending subcutaneous dose study to evaluate the safety, tolerability and pharmcokinetics of BMS-986089 in ambulatory boys with Duchenne muscular dystrophy.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Peter T. Heydemann, MD
Clinical Trial Protocol Description: 

The purpose of this study is to assess the safety and tolerability of an anti-myostatin adnectin called BMS-986089 in ambulatory boys with genetically confirmed Duchenne muscular dystrophy (DMD).

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Be male, 5 to 10 years old and ambulatory without assistance.
  • Weigh at least 15 kg.
  • Have a diagnosis of DMD, confirmed by genotyping.
  • Are receiving corticosteroids (eg, prednisone, prednisolone, or deflazacort) for at least 6 months prior to the start of study drug administration.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a history of current renal disease.
  • Have ejection fraction < 55% on screening echocardiogram.
  • Have known cognitive impairment or behavioral issues that will compromise ability to comply with study procedure.
  • Have uncontrolled clinical signs and symptoms of chronic heart failure (American College of Cardiology/American Heart Associated Stage C or D).

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Pediatric Neurological Disorders
Contact Phone: 
(312) 942-0079
Contact Name: 
Susan Rohde